Literature DB >> 1351970

Formoterol, fenoterol, and salbutamol as partial agonists for relaxation of maximally contracted guinea pig tracheae: comparison of relaxation with receptor binding.

H Lemoine1, C Overlack, A Köhl, H Worth, D Reinhardt.   

Abstract

In severe asthma attacks beta 2-sympathomimetics lose part of their therapeutic efficiency. To elucidate this loss of efficiency in an experimental model we compared the relaxant potency of salbutamol (SAL), fenoterol (FEN), formoterol (FOR), and (-)-isoprenaline (ISO) in guinea pig tracheae partially and maximally precontracted by 0.1 and 60 mumol/L carbachol, respectively. In partially precontracted tracheae the beta 2-sympathomimetics exerted maximum relaxation in comparison with ISO and low EC50S (nmol/L) for relaxation (SAL, 20; FEN, 5.6; FOR, 0.28; and ISO, 2.5). In maximally precontracted tracheae, however, the beta 2-sympathomimetics were only partial agonists for relaxation with reduced intrinsic activities (%) in comparison to ISO (SAL, 59%; FEN, 61%; FOR, 76%) and significantly increased EC50S (nmol/L) for relaxation (SAL, 130; FEN, 57; FOR, 3.0; ISO, 37). To investigate if the high relaxant potency of FOR is correlated with a higher binding affinity and/or a higher intrinsic activity for adenylate cyclase stimulation than for FEN and SAL, we performed experiments in receptor membranes from guinea pig lung. Binding competition of SAL, FEN, and FOR with [3H]ICI 118,551 for lung beta 2-adrenoceptors yielded dissociation constants (KD) of 320 (SAL), 120 (FEN), and 7.6 (FOR) nmol/L, which exhibited the same ranking as EC50S for relaxation. Concentrations of SAL, FEN, and FOR equivalent to 100 KD of the respective dissociation constants stimulated beta 2-adrenoceptor-coupled adenylate cyclase with different intrinsic activities (%) incomparison to ISO (SAL, 61%; FEN, 63%; FOR, 89%) matching intrinsic activities for relaxation. From these experiments it may be concluded that FOR might improve drug therapy of severe asthma not only due to its long mode of action discovered in clinical studies but also due to its high intrinsic activity and receptor affinity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1351970     DOI: 10.1007/bf00174319

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  42 in total

Review 1.  The challenge of long-acting beta-adrenoceptor agonists.

Authors:  K F Rabe; K F Chung
Journal:  Respir Med       Date:  1991-01       Impact factor: 3.415

2.  Evidence that the efficacy (intrinsic activity) of fenoterol is higher than that of salbutamol on beta-adrenoceptors in guinea-pig trachea.

Authors:  S R O'Donnell; J C Wanstall
Journal:  Eur J Pharmacol       Date:  1978-02-01       Impact factor: 4.432

3.  Evidence for a direct relationship between phosphoinositide metabolism and airway smooth muscle contraction induced by muscarinic agonists.

Authors:  H Meurs; A F Roffel; J B Postema; A Timmermans; C R Elzinga; H F Kauffman; J Zaagsma
Journal:  Eur J Pharmacol       Date:  1988-11-01       Impact factor: 4.432

Review 4.  Neural control of human airways in health and disease.

Authors:  P J Barnes
Journal:  Am Rev Respir Dis       Date:  1986-12

5.  Dose-response curves to inhaled beta-adrenoceptor agonists in normal and asthmatic subjects.

Authors:  P J Barnes; N B Pride
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

6.  Improved evaluation of binding of ligands to membranes containing several receptor-subtypes.

Authors:  B Ehle; H Lemoine; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-10       Impact factor: 3.000

Review 7.  Phosphoinositide metabolism in airway smooth muscle.

Authors:  E R Chilvers; S R Nahorski
Journal:  Am Rev Respir Dis       Date:  1990-03

8.  Neuronally released (-)-noradrenaline relaxes smooth muscle of calf trachea mainly through beta 1-adrenoceptors: comparison with (-)-adrenaline and relation to adenylate cyclase stimulation.

Authors:  H Lemonine; G E Novotny; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989 Jan-Feb       Impact factor: 3.000

9.  Formoterol fumarate, a new beta 2-adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration.

Authors:  C G Löfdahl; N Svedmyr
Journal:  Allergy       Date:  1989-05       Impact factor: 13.146

10.  Stimulant and blocking effects of optical isomers of pindolol on the sinoatrial node and trachea of guinea pig. Role of beta-adrenoceptor subtypes in the dissociation between blockade and stimulation.

Authors:  M Walter; H Lemoine; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-09       Impact factor: 3.000

View more
  5 in total

1.  Cardiac implications for the use of beta2-adrenoceptor agonists for the management of muscle wasting.

Authors:  Peter Molenaar; Lu Chen; William A Parsonage
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

2.  Comparison of R-, S-, and RS-albuterol interaction with human beta 1- and beta 2-adrenergic receptors.

Authors:  R B Penn; T Frielle; J R McCullough; G Aberg; J L Benovic
Journal:  Clin Rev Allergy Immunol       Date:  1996       Impact factor: 8.667

Review 3.  Current issues with beta2-adrenoceptor agonists: pharmacology and molecular and cellular mechanisms.

Authors:  Gary P Anderson
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

Review 4.  Budesonide/formoterol combination in COPD: a US perspective.

Authors:  Amir Sharafkhaneh; Amarbir S Mattewal; Vinu M Abraham; Goutham Dronavalli; Nicola A Hanania
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-10-05

5.  Elastase-Induced Parenchymal Disruption and Airway Hyper Responsiveness in Mouse Precision Cut Lung Slices: Toward an Ex vivo COPD Model.

Authors:  Eline M Van Dijk; Sule Culha; Mark H Menzen; Cécile M Bidan; Reinoud Gosens
Journal:  Front Physiol       Date:  2017-01-04       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.